p.116 抽出テキスト

PMID: 30354657 470. Vitali Serdoz L, Rittger H, Furlanello F, et al. Quinidine-A legacy within the modern era of antiarrhythmic therapy. Pharmacol Res 2019; 144: 257-263. PMID: 31026503 471. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110: 1731- 1737. PMID: 15381640 472. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43: 1853-1860. PMID: 15145111 473. Andorin A, Gourraud JB, Mansourati J, et al. The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm 2017; 14: 1147- 1154. PMID: 28411139 474. Anguera I, García-Alberola A, Dallaglio P, et al. Shock Reduction With Long-Term Quinidine in Patients With Brugada Syndrome and Malignant Ventricular Arrhythmia Episodes. J Am Coll Cardiol 2016; 67: 1653-1654. PMID: 27150692 475. Márquez MF, Bonny A, Hernández-Castillo E, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 2012; 9: 1995- 2000. PMID: 23059185 476. Belhassen B, Rahkovich M, Michowitz Y, et al. Management of Brugada Syndrome: Thirty-Three-Year Experience Using Electrophysiologically Guided Therapy With Class 1A Antiarrhythmic Drugs. Circ Arrhythm Electrophysiol 2015; 8: 1393-1402. PMID: 26354972 477. Kang L, Zheng MQ, Morishima M, et al. Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity. Br J Pharmacol 2009; 157: 404-414. PMID: 19371335 478. Murakami M, Nakamura K, Kusano KF, et al. Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. J Cardiovasc Pharmacol 2010; 56: 389-395. PMID: 20625312 479. Aizawa Y, Yamakawa H, Takatsuki S, et al. Efficacy and safety of bepridil for prevention of ICD shocks in patients with Brugada syndrome and idiopathic ventricular fibrillation. Int J Cardiol 2013; 168: 5083-5085. PMID: 23954005 480. Brodie OT, Michowitz Y, Belhassen B. Pharmacological Therapy in Brugada Syndrome. Arrhythm Electrophysiol Rev 2018; 7: 135-142. PMID: 29967687 481. Szél T, Koncz I, Antzelevitch C. Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. Heart Rhythm 2013; 10: 1720- 1727. PMID: 23911896 482. Tsuchiya T, Ashikaga K, Honda T, et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13: 698-701. PMID: 12139296 483. Watanabe A, Fukushima Kusano K, Morita H, et al. Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome. Eur Heart J 2006; 27: 1579-1583. PMID: 16760208 484. Ohgo T, Okamura H, Noda T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007; 4: 695-700. PMID: 17556186 485. Shinohara T, Ebata Y, Ayabe R, et al. Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. Heart Rhythm 2014; 11: 1441-1445. PMID: 24813378 486. Nademanee K, Veerakul G, Mower M, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107: 2221-2226. PMID: 12695290 487. Nogami A, Kurita T, Abe H, et al. JCS/JHRS Joint Working Group. JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Circ J 2021; 85: 1104-1244. PMID: 34078838 488. Tonegawa-Kuji R, Inoue YY, Nakai M, et al. Current clinical practice of subcutaneous implantable cardioverter-defibrillator: Analysis using the JROAD-DPC database. Heart Rhythm 2022; 19: 909-916. PMID: 35158088 489. Gourraud JB, Sacher F, Badenco N, et al. Subcutaneous implantable cardiac defibrillator in Brugada syndrome: a prospective multicentre study. Eur Heart J 2026; 47: 269-271. PMID: 41055900 490. Migliore F, Ottaviano L, Arestia A, et al. S-ICD Rhythm Detect Investigators. Subcutaneous Implantable Defibrillator Therapy in Patients With Brugada Syndrome: Data From a Large Multicenter Registry. JACC Clin Electrophysiol 2025; 11: 1572-1582. PMID: 40156599 491. Kamakura T, Sato T, Wada M, et al. T-wave oversensing during drug challenge test after subcutaneous implantable cardioverterdefibrillator implantation in a patient with Brugada syndrome. HeartRhythm Case Rep 2016; 2: 391-394. PMID: 28491718 492. Kamakura T, Wada M, Ishibashi K, et al. Impact of electrocardiogram screening during drug challenge test for the prediction of T-wave oversensing by a subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome. Heart Vessels 2017; 32: 1277-1283. PMID: 28523371 493. Kawabata M, Goya M, Sasaki T, et al. Surface Electrocardiogram Screening for Subcutaneous Implantable Cardioverter-Defibrillators in Japanese Patients With and Without Brugada Syndrome. Circ J 2017; 81: 981-987. PMID: 28367844 494. Tachibana M, Nishii N, Morita H, et al. Exercise stress test reveals ineligibility for subcutaneous implantable cardioverter defibrillator in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2017; 28: 1454-1459. PMID: 28800177 495. Conte G, Kawabata M, de Asmundis C, et al. High rate of subcutaneous implantable cardioverter-defibrillator sensing screening failure in patients with Brugada syndrome: a comparison with other inherited primary arrhythmia syndromes. Europace 2018; 20: 1188- 1193. PMID: 28340026 496. Russo V, Caturano A, Guerra F, et al. IBRYD Study Group. Subcutaneous versus transvenous implantable cardioverter-defibrillator among drug-induced type-1 ECG pattern Brugada syndrome: a propensity score matching analysis from IBRYD study. Heart Vessels 2023; 38: 680-688. PMID: 36418560 497. Talib AK, Takagi M, Shimane A, et al. Efficacy of Endocardial Ablation of Drug-Resistant Ventricular Fibrillation in Brugada Syndrome: Long-Term Outcome. Circ Arrhythm Electrophysiol 2018; 11: e005631. PMID: 30354308 498. Brugada J, Pappone C, Berruezo A, et al. Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. Circ Arrhythm Electrophysiol 2015; 8: 1373-1381. PMID: 26291334 499. Zhang P, Tung R, Zhang Z, et al. Characterization of the epicardial substrate for catheter ablation of Brugada syndrome. Heart Rhythm 2016; 13: 2151-2158. PMID: 27453126 500. Pappone C, Brugada J, Vicedomini G, et al. Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome. Circ Arrhythm Electrophysiol 2017; 10: e005053. PMID: 28500178 501. Nademanee K, Haissaguerre M, Hocini M, et al. Mapping and Ablation of Ventricular Fibrillation Associated With Early Repolarization Syndrome. Circulation 2019; 140: 1477-1490. PMID: 31542949 502. Cheniti G, Haissaguerre M, Dina C, et al. Left Ventricular Abnormal Substrate in Brugada Syndrome. JACC Clin Electrophysiol 2023; 9: 2041-2051. PMID: 37480873 503. Kamakura T, Cochet H, Juhoor M, et al. Role of endocardial ablation in eliminating an epicardial arrhythmogenic substrate in patients with Brugada syndrome. Heart Rhythm 2021; 18: 1673- 1681. PMID: 34182174 504. Conte G, Probst V. Time to consider catheter ablation as an alternative to implantable cardioverter-defibrillator therapy in highrisk patients with Brugada syndrome? Europace 2023; 25: euad338. PMID: 37949829 505. Li L, Ding L, Zhou L, et al. Outcomes of catheter ablation in highrisk patients with Brugada syndrome refusing an implantable cardioverter defibrillator implantation. Europace 2023; 26: euad318. PMID: 37889958 506. Nademanee K, Wongcharoen W, Chimparlee N, et al. Brugada Syndrome Ablation for the Prevention of Ventricular Fibrillation Episodes (BRAVE). Heart Rhythm 2025; 22: 1975-1983. PMID: 40294736 507. Pappone C, Ciconte G, Vicedomini G, et al. Epicardial ablation in high-risk Brugada syndrome to prevent ventricular fibrillation: results from a randomized clinical trial. Europace 2025; 27: euaf097. PMID: 40401314 508. Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40: 1437-1444. PMID: 12392834 509. Sairaku A, Yoshida Y, Nakano Y, et al. Ablation of atrial fibrillation in Brugada syndrome patients with an implantable cardioverter defibrillator to prevent inappropriate shocks resulting from rapid atrial fibrillation. Int J Cardiol 2013; 168: 5273-5276. PMID: 23988302 510. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512-1519. PMID: 7867192